search
Back to results

Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL) (IRONCEL)

Primary Purpose

Celiac Disease

Status
Not yet recruiting
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Ferinject
oral iron
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Celiac Disease focused on measuring Celiac disease, Iron deficiency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients free of mental illness, able to sign consent and >18year
  • Celiac disease confirmed by presence of serum celiac antibodies and villous atrophy on intestinal biopsy before starting gluten free diet (GFD)
  • Intestinal villous atrophy on duodenal biopsy (performed within 1 month) showing villous atrophy
  • Patient under GFD or starting GFD with strict compliance
  • Hemoglobin level (Hb) <12g/dL & Hb>8g/dL
  • Well tolerated anemia
  • Iron deficiency defined by: serum iron level < 11 µmol/L, ferritinemia < 20µg/L and/or transferrin saturation index <0.2

Exclusion Criteria:

  • Patient not able to sign, mental illness, pregnancy
  • Complicated celiac disease: intestinal malignancies
  • Severe anemia (Hb <8g/dL) and/or poorly tolerated anemia requiring systematic iron IV supplementation or blood transfusion
  • Serious severe disease having short-term prognostic implication
  • Contraindication to intravenous iron infusion: known drug allergy
  • Pregnant or breastfeeding women
  • Participation in another interventional trial
  • Patients treated by steroids, immunosuppressors or chemotherapy drugs

Sites / Locations

  • Hôpital Cochin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Oral Iron + IV Ferinject

Oral Iron only

Arm Description

Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year.

Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).

Outcomes

Primary Outcome Measures

Total villous recovery
The primary endpoint is the proportion of patients with total villous recovery (total remission) on the last duodenal biopsies. 6 formalin and 2 frozen duodenal biopsies will be performed. Intestinal mucosal assessment will be performed by a centralized histological analysis according to the Marsh classification. Readers will be blind to the treatment received.

Secondary Outcome Measures

Atrophic gastritis
Proportion of patients with atrophic gastritis at V0 and at V14 biopsies (2 in the antrum, 1 in the angulus and 2 in the fundus)
Partial recovery of intestinal villous atrophy
Proportion of patients with partial recovery of intestinal villous atrophy on the last control duodenal biopsies according to Marsh classification (centralized histological analysis). Six formalin and two frozen duodenal biopsies will be performed.
Iron deficiency
Proportion of patients correcting iron deficiency. Iron parameters (serum iron level (µmol/L), ferritinemia (µg/L), transferrin saturation index) will be assessed at visit V1, V3, V6, V10, V14; correction of iron deficiency is defined by serum iron level > 20 µg/L and transferrin saturation index ≥0.20.
Anaemia
Proportion of patients correcting anaemia during the 12 months participation. Hemoglobin (Hb) level (g/d) will be measured at visit V1, V3, V6, V10, V14. Correction of anaemia is defined by Hb≥12g/L in woman and Hb≥13g/dL in man.
Intraepithelial lymphocytes
Evolution of the count of intraepithelial lymphocytes assessed on initial and last control biopsy.
CD71 on epithelial cells
Evolution of the expression of CD71 on epithelial cells studied on initial and last control biopsy
Body Mass Index
Evolution of the patient's BMI during his participation at the study.
Serum folate level
Serum folate level (µg/L) measured at visit V1, V3, V6, V10, V14.
Vitamin B12 level
Level of vitamin B12 (pmol/L) measured at visit V1, V3, V6, V10, V14.
Calcemia level
Level of calcemia (mmol/L) measured at visit V1, V3, V6, V10, V14.
Albuminemia level
Level of albuminemia (g/L) measured at visit V1, V3, V6, V10, V14.
Corrected calcemia level
Level of corrected calcemia (mmol/L) measured at visit V1, V3, V6, V10, V14.
25(OH)D3 vitamin level
Level of 25(OH)D3 vitamin measured at visit V1, V3, V6, V10, V14.
Liver enzymes
Evolution of serum levels of liver enzymes (AST, ALT, AP, gGT, Total Bilirubin), glycemia, T4, TSH measured at visit V1, V3, V6, V10, V14.
Gluten free diet
Observance of gluten free diet will be assessed by (i) dietitian assessment of gluten free consumption (g/day and proportion of patients in high (0 g/day), medium (0-50 mg/day), low (>50 mg/day) observance), (ii) measurement of serum celiac antibodies (anti-tTG IgA and anti-deamidated gliadin IgG) and (iii) proportion of patients having gluten immunogenic peptides excretion detected in urine at visit V1, V3, V6,V10, V14.
Patient quality of life
French Celiac disease questionnaire assessed at V1 and V14 about the evolution of the quality of life for the patient.

Full Information

First Posted
September 9, 2021
Last Updated
January 17, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministry of Health, France
search

1. Study Identification

Unique Protocol Identification Number
NCT05114278
Brief Title
Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL)
Acronym
IRONCEL
Official Title
Effect of Intravenous Iron Supplementation on Celiac Disease Remission in Patients With Iron Deficiency and Intestinal Villous Atrophy: a Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 15, 2022 (Anticipated)
Primary Completion Date
April 15, 2026 (Anticipated)
Study Completion Date
April 15, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Ministry of Health, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims is to evaluate the efficacy of intravenous iron supplementation on celiac disease remission (total intestinal mucosal recovery). This randomized multicenter trial compare the administration of intravenous iron by infusion (Ferinject©: 15 mg/kg in NaCl solution in 30 min) and oral iron in combination; to patients receive only oral iron as standard care. The first benefit with IV Iron supplementation is to correct iron deficiency more rapidly than oral iron alone because of trouble of absorption in case of intestinal villous atrophy.
Detailed Description
Celiac disease is an autoimmune-like disorder induced in genetically predisposed individuals by dietary proteins from wheat (gluten). Its frequency reaches 1% in Europe. In celiac patients, gluten induces small intestinal villous atrophy and, as a consequence, malnutrition. Celiac disease treatment relies on a long-life strict gluten-free diet that allows clinical and histological recovery and prevents long-term complications (autoimmune diseases, osteoporosis and malignancies). Remission is attested by total villous recovery on duodenal biopsy performed after one year of gluten free diet. Yet, in adults, systematic follow-up of biopsies for several years after gluten free diet initiation has recently revealed persistent villous atrophy in more than 40 % of cases with an increased risk in older patients (up to 56%). Lack of mucosal healing has been associated with the risk of complications in celiac, notably a risk factor for fractures and lymphoma. It is therefore necessary to define strategies to obtain and accelerate full recovery. Iron deficiency is strongly associated with celiac disease and is generally viewed as a consequence of small intestinal lesions and a symptom of malnutrition. Our preliminary clinical retrospective study showed more frequent iron deficiency anemia in celiac patients with (20/70; 29%) than without (11/88; 12.5%) villous atrophy (p = 0.015; OR: 2.78). Our previous experimental study suggests that iron deficiency may sustain tissue damage and delay mucosal recovery in celiac disease. Indeed the transferrin receptor (CD71) is overexpressed in the gut epithelium in case of iron deficiency and can interact with secretory IgA1 present in large amounts in the intestinal lumen of CD patients. Crosslinking of CD71 by polymeric IgA1 can induce production of inflammatory cytokines. Our working hypothesis is therefore that iron deficiency maintains aberrant expression of CD71 at the gut epithelial surface that sustains intestinal inflammation and epithelial damage. Iron supplementation of celiac patients with villous atrophy and iron deficiency may accelerate mucosal healing, villous recovery and remission.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease
Keywords
Celiac disease, Iron deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Phase IV, open, randomized, 2-arms parallel controlled trial with blinded assessment of end-point.
Masking
Outcomes Assessor
Masking Description
Upper endoscopy with duodenal biopsy will be performed at most one month before randomization, and one month after the last infusion (experimental group) and between the 12th and the 13h month after randomization (control group). Histological analysis (villous recovery, primary endpoint) will be centrally performed by an expert pathologist blind to the group of treatment.
Allocation
Randomized
Enrollment
204 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Oral Iron + IV Ferinject
Arm Type
Experimental
Arm Description
Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year.
Arm Title
Oral Iron only
Arm Type
Active Comparator
Arm Description
Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
Intervention Type
Drug
Intervention Name(s)
Ferinject
Other Intervention Name(s)
Experimental arm
Intervention Description
Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
Intervention Type
Drug
Intervention Name(s)
oral iron
Other Intervention Name(s)
Control arm
Intervention Description
All patients will receive an oral iron supplementation (100mg/day).
Primary Outcome Measure Information:
Title
Total villous recovery
Description
The primary endpoint is the proportion of patients with total villous recovery (total remission) on the last duodenal biopsies. 6 formalin and 2 frozen duodenal biopsies will be performed. Intestinal mucosal assessment will be performed by a centralized histological analysis according to the Marsh classification. Readers will be blind to the treatment received.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Atrophic gastritis
Description
Proportion of patients with atrophic gastritis at V0 and at V14 biopsies (2 in the antrum, 1 in the angulus and 2 in the fundus)
Time Frame
12 months
Title
Partial recovery of intestinal villous atrophy
Description
Proportion of patients with partial recovery of intestinal villous atrophy on the last control duodenal biopsies according to Marsh classification (centralized histological analysis). Six formalin and two frozen duodenal biopsies will be performed.
Time Frame
12 months
Title
Iron deficiency
Description
Proportion of patients correcting iron deficiency. Iron parameters (serum iron level (µmol/L), ferritinemia (µg/L), transferrin saturation index) will be assessed at visit V1, V3, V6, V10, V14; correction of iron deficiency is defined by serum iron level > 20 µg/L and transferrin saturation index ≥0.20.
Time Frame
12 months
Title
Anaemia
Description
Proportion of patients correcting anaemia during the 12 months participation. Hemoglobin (Hb) level (g/d) will be measured at visit V1, V3, V6, V10, V14. Correction of anaemia is defined by Hb≥12g/L in woman and Hb≥13g/dL in man.
Time Frame
12 months
Title
Intraepithelial lymphocytes
Description
Evolution of the count of intraepithelial lymphocytes assessed on initial and last control biopsy.
Time Frame
12 months
Title
CD71 on epithelial cells
Description
Evolution of the expression of CD71 on epithelial cells studied on initial and last control biopsy
Time Frame
12 months
Title
Body Mass Index
Description
Evolution of the patient's BMI during his participation at the study.
Time Frame
12 months
Title
Serum folate level
Description
Serum folate level (µg/L) measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
Vitamin B12 level
Description
Level of vitamin B12 (pmol/L) measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
Calcemia level
Description
Level of calcemia (mmol/L) measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
Albuminemia level
Description
Level of albuminemia (g/L) measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
Corrected calcemia level
Description
Level of corrected calcemia (mmol/L) measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
25(OH)D3 vitamin level
Description
Level of 25(OH)D3 vitamin measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
Liver enzymes
Description
Evolution of serum levels of liver enzymes (AST, ALT, AP, gGT, Total Bilirubin), glycemia, T4, TSH measured at visit V1, V3, V6, V10, V14.
Time Frame
12 months
Title
Gluten free diet
Description
Observance of gluten free diet will be assessed by (i) dietitian assessment of gluten free consumption (g/day and proportion of patients in high (0 g/day), medium (0-50 mg/day), low (>50 mg/day) observance), (ii) measurement of serum celiac antibodies (anti-tTG IgA and anti-deamidated gliadin IgG) and (iii) proportion of patients having gluten immunogenic peptides excretion detected in urine at visit V1, V3, V6,V10, V14.
Time Frame
12 months
Title
Patient quality of life
Description
French Celiac disease questionnaire assessed at V1 and V14 about the evolution of the quality of life for the patient.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients free of mental illness, able to sign consent and >18year Celiac disease confirmed by presence of serum celiac antibodies and villous atrophy on intestinal biopsy before starting gluten free diet (GFD) Intestinal villous atrophy on duodenal biopsy (performed within 1 month) showing villous atrophy Patient under GFD or starting GFD with strict compliance Hemoglobin level (Hb) <12g/dL & Hb>8g/dL Well tolerated anemia Iron deficiency defined by: serum iron level < 11 µmol/L, ferritinemia < 20µg/L and/or transferrin saturation index <0.2 Exclusion Criteria: Patient not able to sign, mental illness, pregnancy Complicated celiac disease: intestinal malignancies Severe anemia (Hb <8g/dL) and/or poorly tolerated anemia requiring systematic iron IV supplementation or blood transfusion Serious severe disease having short-term prognostic implication Contraindication to intravenous iron infusion: known drug allergy Pregnant or breastfeeding women Participation in another interventional trial Patients treated by steroids, immunosuppressors or chemotherapy drugs
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Karine GOUDE-ORY, MSc
Phone
+33144841722
Email
karine.goude@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Sabrina BOUDIF, MSc
Phone
+33156095976
Email
sabrina.boudif@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georgia MALAMUT, MD, PhD
Organizational Affiliation
Cochin, AP-HP, Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Cochin
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georgia MALAMUT, MD, PhD
First Name & Middle Initial & Last Name & Degree
Georgia MALAMUT, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared
IPD Sharing Time Frame
Two years after the last publication
IPD Sharing Access Criteria
Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and PI team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractual agreement. Processing of shared data must comply with European General Data Protection Regulation (GDPR).

Learn more about this trial

Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL)

We'll reach out to this number within 24 hrs